A randomised, controlled trial of bosentan in severe COPD
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 1194066
Author(s) Stolz, D; Rasch, H; Linka, A; Di Valentino, M; Meyer, A; Brutsche, M; Tamm, M
Author(s) at UniBasel Tamm, Michael
Brutsche, Martin
Year 2008
Title A randomised, controlled trial of bosentan in severe COPD
Journal The European respiratory journal
Volume 32
Number 3
Pages / Article-Number 619-28
Keywords endothelin-receptor antagonist, exercise capacity, pulmonary hypertension, treatment
Abstract Pulmonary hypertension during exercise is common in severe chronic obstructive pulmonary disease (COPD). It was hypothesised that the use of the endothelin-receptor antagonist bosentan can improve cardiopulmonary haemodynamics during exercise, thus increasing exercise tolerance in patients with severe COPD. In the present double-blind, placebo-controlled study, 30 patients with severe or very severe COPD were randomly assigned in a 2:1 ratio to receive either bosentan or placebo for 12 weeks. The primary end-point was change in the 6-min walking distance. Secondary end-points included changes in health-related quality of life, lung function, cardiac haemodynamics, maximal oxygen uptake and pulmonary perfusion patterns. Compared with placebo, patients treated with bosentan during 12 weeks showed no significant improvement in exercise capacity as measured by the 6-min walking distance (mean+/-SD 331+/-123 versus 329+/-94 m). There was no change in lung function, pulmonary arterial pressure, maximal oxygen uptake or regional pulmonary perfusion pattern. In contrast, arterial oxygen pressure dropped, the alveolar-arterial gradient increased and quality of life deteriorated significantly in patients assigned bosentan. The oral administration of the endothelin receptor antagonist bosentan not only failed to improve exercise capacity but also deteriorated hypoxaemia and functional status in severe chronic obstructive pulmonary disease patients without severe pulmonary hypertension at rest.
Publisher Munksgaard
ISSN/ISBN 0903-1936
edoc-URL http://edoc.unibas.ch/dok/A6004297
Full Text on edoc No
Digital Object Identifier DOI 10.1183/09031936.00011308
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/18448495
ISI-Number WOS:000259433100014
Document type (ISI) Journal Article, Randomized Controlled Trial
 
   

MCSS v5.8 PRO. 0.444 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
07/08/2020